Accounts Payable, Current in USD of BIO-RAD LABORATORIES, INC. from Q4 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Bio Rad Laboratories, Inc. quarterly Accounts Payable, Current history and change rate from Q4 2010 to Q3 2025.
  • Bio Rad Laboratories, Inc. Accounts Payable, Current for the quarter ending 30 Sep 2025 was $129M, a 5.41% increase year-over-year.
Accounts Payable, Current, Quarterly (USD)
Accounts Payable, Current, YoY Quarterly Change (%)

BIO-RAD LABORATORIES, INC. Quarterly Accounts Payable, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $129M +$6.62M +5.41% 30 Sep 2025 10-Q 29 Oct 2025
Q2 2025 $139M +$12.6M +9.95% 30 Jun 2025 10-Q 31 Jul 2025
Q1 2025 $138M +$35.2M +34.2% 31 Mar 2025 10-Q 01 May 2025
Q4 2024 $122M -$22.3M -15.4% 31 Dec 2024 10-Q 29 Oct 2025
Q3 2024 $122M +$10.3M +9.23% 30 Sep 2024 10-Q 31 Oct 2024
Q2 2024 $127M -$22.8M -15.3% 30 Jun 2024 10-Q 02 Aug 2024
Q1 2024 $103M -$58.2M -36.2% 31 Mar 2024 10-Q 08 May 2024
Q4 2023 $145M +$9.56M +7.08% 31 Dec 2023 10-K 14 Feb 2025
Q3 2023 $112M -$30.9M -21.6% 30 Sep 2023 10-Q 27 Oct 2023
Q2 2023 $150M -$8.72M -5.51% 30 Jun 2023 10-Q 04 Aug 2023
Q1 2023 $161M +$328K +0.2% 31 Mar 2023 10-Q 05 May 2023
Q4 2022 $135M -$6.9M -4.86% 31 Dec 2022 10-K 16 Feb 2024
Q3 2022 $143M +$6.35M +4.65% 30 Sep 2022 10-Q 28 Oct 2022
Q2 2022 $158M +$24.8M +18.6% 30 Jun 2022 10-Q 29 Jul 2022
Q1 2022 $161M +$22.2M +16% 31 Mar 2022 10-Q 29 Apr 2022
Q4 2021 $142M +$2.49M +1.79% 31 Dec 2021 10-K 17 Feb 2023
Q3 2021 $136M +$3.4M +2.56% 30 Sep 2021 10-Q 29 Oct 2021
Q2 2021 $133M 30 Jun 2021 10-Q 30 Jul 2021
Q1 2021 $138M 31 Mar 2021 10-Q 30 Apr 2021
Q4 2020 $139M +$32.4M +30.3% 31 Dec 2020 10-K 11 Feb 2022
Q3 2020 $133M 30 Sep 2020 10-Q 30 Oct 2020
Q4 2019 $107M -$15.4M -12.6% 31 Dec 2019 10-K 16 Feb 2021
Q4 2018 $122M -$12.7M -9.42% 31 Dec 2018 10-K 02 Mar 2020
Q4 2017 $135M +$2.07M +1.56% 31 Dec 2017 10-K 01 Apr 2019
Q4 2016 $133M +$10.7M +8.76% 31 Dec 2016 10-K 16 Apr 2018
Q4 2015 $122M -$6.22M -4.83% 31 Dec 2015 10-K 01 Mar 2017
Q4 2014 $129M -$19.9M -13.4% 31 Dec 2014 10-K 29 Feb 2016
Q3 2014 $127M -$5.26M -3.99% 30 Sep 2014 10-Q 07 Nov 2014
Q2 2014 $125M -$3.66M -2.83% 30 Jun 2014 10-Q 06 Aug 2014
Q1 2014 $131M +$11.5M +9.66% 31 Mar 2014 10-Q 08 May 2014
Q4 2013 $149M +$17.6M +13.5% 31 Dec 2013 10-K 02 Mar 2015
Q3 2013 $132M +$18.6M +16.4% 30 Sep 2013 10-Q 12 Nov 2013
Q2 2013 $129M +$9.67M +8.1% 30 Jun 2013 10-Q 08 Aug 2013
Q1 2013 $119M +$9.77M +8.92% 31 Mar 2013 10-Q 10 May 2013
Q4 2012 $131M +$1.74M +1.35% 31 Dec 2012 10-K 18 Mar 2014
Q3 2012 $113M -$194K -0.17% 30 Sep 2012 10-Q 08 Nov 2012
Q2 2012 $119M -$1.07M -0.89% 30 Jun 2012 10-Q 09 Aug 2012
Q1 2012 $110M 31 Mar 2012 10-Q 10 May 2012
Q4 2011 $129M +$15.7M +13.8% 31 Dec 2011 10-K 18 Mar 2013
Q3 2011 $113M 30 Sep 2011 10-Q 03 Nov 2011
Q2 2011 $121M 30 Jun 2011 10-Q 04 Aug 2011
Q4 2010 $113M 31 Dec 2010 10-K 29 Feb 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.